Serum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various grades

Neuro-Oncology

Volumn 12, Issue 2, 2010, Pages 173-180

  Lavon, Iris ^a   Refael, Miri ^a   Zelikovitch, Bracha ^a   Shalom, Edna ^a   Siegal, Tali ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Allelic loss; Astrocytoma; Chromosomal deletion; Circulating DNA; Glioblastoma multiforme; Glioma; MGMT; Promoter methylation; PTEN

Indexed keywords

DNA; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASTROCYTOMA; CANCER GENETICS; CHROMOSOME 10Q; CHROMOSOME 19Q; CHROMOSOME 1P; DNA DETERMINATION; DNA METHYLATION; EARLY CANCER; EPIGENETICS; FEMALE; GLIOMA; HETEROZYGOSITY LOSS; HUMAN; MAJOR CLINICAL STUDY; MALE; OLIGODENDROGLIOMA; POLYMERASE CHAIN REACTION; PROMOTER REGION; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; BRAIN NEOPLASMS; DNA; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; EPIGENESIS, GENETIC; FEMALE; GLIOMA; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; POLYMERASE CHAIN REACTION; PTEN PHOSPHOHYDROLASE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 75849139815     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nop041     Document Type: Article

References (37)

1. Jahr S, Hentze H, Englisch S, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001;61(4):1659-1665.
2. Giacona MB, Ruben GC, Iczkowski KA, Roos TB, Porter DM, Sorenson GD. Cell-free DNA in human blood plasma: length measurements in patients with pancreatic cancer and healthy controls. Pancreas. 1998;17(1):89-97.
3. Tsang JC, Lo YM. Circulating nucleic acids in plasma/serum. Pathology. 2007;39(2):197-207.
4. Vlassov VV, Laktionov PP, Rykova EY. Extracellular nucleic acids. Bioessays. 2007;29(7):654-667.
5. Skvortsova TE, Rykova EY, Tamkovich SN, et al. Cell-free and cellbound circulating DNA in breast tumours: DNA quantification and analysis of tumour-related gene methylation. Br J Cancer. 2006;94(10):1492-1495.
6. Rykova EY, Wunsche W, Brizgunova OE, et al. Concentrations of circulating RNA from healthy donors and cancer patients estimated by different methods. Ann N Y Acad Sci. 2006;1075:328-333.
7. Bremnes RM, Sirera R, Camps C. Circulating tumour-derived DNA and RNA markers in blood: a tool for early detection, diagnostics, and follow-up? Lung Cancer. 2005;49(1):1-12.
8. Chan KC, Lo YM. Circulating tumour-derived nucleic acids in cancer patients: potential applications as tumour markers. Br J Cancer. 2007;96(5):681-685.
9. Ramirez JL, Taron M, Balana C, et al. Serum DNA as a tool for cancer patient management. Rocz Akad Med Bialymst. 2003;48:34-41.
10. Schwarzenbach H, Chun FK, Muller I, et al. Microsatellite analysis of allelic imbalance in tumour and blood from patients with prostate cancer. BJU Int. 2008;102(2):253-258.
11. Stroun M, Anker P, Maurice P, Lyautey J, Lederrey C, Beljanski M. Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology. 1989;46(5):318-322.
12. 6-Methyl- guanine-DNA methyl-transferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme. Clin Cancer Res. 2003;9(4):1461-1468.
13. Umetani N, Giuliano AE, Hiramatsu SH, et al. Prediction of breast tumor progression by integrity of free circulating DNA in serum. J Clin Oncol. 2006;24(26):4270-4276.
14. Sunami E, Shinozaki M, Higano CS, et al. Multimarker circulating DNA assay for assessing blood of prostate cancer patients. Clin Chem. 2009;55(3):559-567.
15. Hisazumi J, Kobayashi N, Nishikawa M, Takakura Y. Significant role of liver sinusoidal endothelial cells in hepatic uptake and degradation of naked plasmid DNA after intravenous injection. Pharm Res. 2004;21(7):1223-1228.
16. Ogawa Y, Yoshinaga T, Yasuda K, Nishikawa M, Takakura Y. The uptake and degradation of DNA is impaired in macrophages and dendritic cells from NZB/W F(1) mice. Immunol Lett. 2005;101(1):32-40.
17. Weaver KD, Grossman SA, Herman JG. Methylated tumor-specific DNA as a plasma biomarker in patients with glioma. Cancer Invest. 2006;24(1):35-40.
18. Chan KC, Lai PB, Mok TS, et al. Quantitative analysis of circulating methylated DNA as a biomarker for hepatocellular carcinoma. Clin Chem. 2008;54(9):1528-1536.
19. Diehl F, Schmidt K, Choti MA, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14(9):985-990.
20. Usadel H, Brabender J, Danenberg KD, et al. Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. Cancer Res. 2002;62(2):371-375.
21. Diehl F, Li M, Dressman D, et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci USA. 2005;102(45):16368-16373.
22. Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, Herman JG. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res. 1999;59(1):67-70.
23. Fujiwara K, Fujimoto N, Tabata M, et al. Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer. Clin Cancer Res. 2005;11(3):1219-1225.
24. Grunau C, Clark SJ, Rosenthal A. Bisulfite genomic sequencing: systematic investigation of critical experimental parameters. Nucleic Acids Res. Jul 1 2001;29(13):E65-E65.
25. Kagan J, Srivastava S, Barker PE, Belinsky SA, Cairns P. Towards clinical application of methylated DNA sequences as cancer biomarkers: a joint NCI's EDRN and NIST workshop on standards, methods, assays, reagents and tools. Cancer Res. 2007;67(10):4545-4549.
26. Jung M, Klotzek S, Lewandowski M, Fleischhacker M, Jung K. Changes in concentration of DNA in serum and plasma during storage of blood samples. Clin Chem. 2003;49(6 Pt 1):1028-1029.
27. Lee TH, Montalvo L, Chrebtow V, Busch MP. Quantitation of genomic DNA in plasma and serum samples: higher concentrations of genomic DNA found in serum than in plasma. Transfusion. 2001;41(2): 276-282.
28. Umetani N, Hiramatsu S, Hoon DS. Higheramount of free circulating DNA in serum than in plasma is not mainly caused by contaminated extraneous DNA during separation. Ann N Y Acad Sci. 2006;1075:299-307.
29. Paci M, Maramotti S, Bellesia E, et al. Circulating plasma DNA as diagnostic biomarker in non-small cell lung cancer. Lung Cancer. 2009;64(1):92-97.
30. 6-methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn. 2008;10(4):332-337.
31. Sawyers CL. The cancer biomarker problem. Nature. 2008;452(7187): 548-552.
32. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10): 997-1003.
33. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000;343(19):1350-1354.
34. Aldape K, Burger PC, Perry A. Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma. Arch Pathol Lab Med. 2007;131(2):242-251.
35. Van den Bent MJ, Reni M, Gatta G, Vecht C. Oligodendroglioma. Crit Rev Oncol Hematol. 2008;66(3):262-272.
36. Lorente A, Mueller W, Urdangarin E, et al. RASSF1A, BLU, NORE1A, PTEN and MGMT expression and promoter methylation in gliomas and glioma cell lines and evidence of deregulated expression of de novo DNMTs. Brain Pathol. 2009;19(2):279-292.
37. MuellerW, Nutt CL, Ehrich M, et al. Downregulation of RUNX3 and TES by hypermethylation in glioblastoma. Oncogene. 2007;26(4):583-593.